ITMI20030821A1 - Polipeptidi chimerici e loro uso. - Google Patents

Polipeptidi chimerici e loro uso.

Info

Publication number
ITMI20030821A1
ITMI20030821A1 IT000821A ITMI20030821A ITMI20030821A1 IT MI20030821 A1 ITMI20030821 A1 IT MI20030821A1 IT 000821 A IT000821 A IT 000821A IT MI20030821 A ITMI20030821 A IT MI20030821A IT MI20030821 A1 ITMI20030821 A1 IT MI20030821A1
Authority
IT
Italy
Prior art keywords
dna
activity
activities
chimeric molecules
polypeptides
Prior art date
Application number
IT000821A
Other languages
English (en)
Inventor
Christian Kuhne
Andras Simoncsits
Original Assignee
Internat Ct For Genetic En Gineering And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Internat Ct For Genetic En Gineering And filed Critical Internat Ct For Genetic En Gineering And
Priority to IT000821A priority Critical patent/ITMI20030821A1/it
Priority to KR1020057019839A priority patent/KR101360781B1/ko
Priority to CA002522525A priority patent/CA2522525A1/en
Priority to ES04727873T priority patent/ES2293247T3/es
Priority to PL04727873T priority patent/PL1616011T3/pl
Priority to US10/546,661 priority patent/US20060292629A1/en
Priority to PCT/EP2004/004062 priority patent/WO2004092194A2/en
Priority to KR1020117013324A priority patent/KR101247704B1/ko
Priority to AU2004230254A priority patent/AU2004230254B2/en
Priority to AT04727873T priority patent/ATE374826T1/de
Priority to DE602004009301T priority patent/DE602004009301T2/de
Priority to PT04727873T priority patent/PT1616011E/pt
Priority to SI200430480T priority patent/SI1616011T1/sl
Priority to EP04727873A priority patent/EP1616011B1/en
Priority to CN200480009095A priority patent/CN100584950C/zh
Priority to JP2006505169A priority patent/JP4794432B2/ja
Priority to DK04727873T priority patent/DK1616011T3/da
Publication of ITMI20030821A1 publication Critical patent/ITMI20030821A1/it
Priority to CY20071101640T priority patent/CY1107115T1/el
Priority to US12/616,859 priority patent/US20110033384A1/en
Priority to JP2011051784A priority patent/JP2011182792A/ja
Priority to US14/479,045 priority patent/US20150018409A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
IT000821A 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso. ITMI20030821A1 (it)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
AT04727873T ATE374826T1 (de) 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung
SI200430480T SI1616011T1 (sl) 2003-04-18 2004-04-16 Himerni polipeptidi in njihova uporaba
ES04727873T ES2293247T3 (es) 2003-04-18 2004-04-16 Polipeptidos quimericos y su utilizacion.
PL04727873T PL1616011T3 (pl) 2003-04-18 2004-04-16 Chimeryczne polipeptydy i ich zastosowanie
US10/546,661 US20060292629A1 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use
PCT/EP2004/004062 WO2004092194A2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use
KR1020117013324A KR101247704B1 (ko) 2003-04-18 2004-04-16 키메라 폴리펩티드 및 이의 용도
AU2004230254A AU2004230254B2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use
KR1020057019839A KR101360781B1 (ko) 2003-04-18 2004-04-16 키메라 폴리펩티드 및 이의 용도
DE602004009301T DE602004009301T2 (de) 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung
PT04727873T PT1616011E (pt) 2003-04-18 2004-04-16 Polipeptídeos quiméricos e a sua utilização
CA002522525A CA2522525A1 (en) 2003-04-18 2004-04-16 Chimeric polypeptides comprising a type ii restriction endonuclease
EP04727873A EP1616011B1 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use
CN200480009095A CN100584950C (zh) 2003-04-18 2004-04-16 嵌合多肽及其用途
JP2006505169A JP4794432B2 (ja) 2003-04-18 2004-04-16 キメラポリペプチドおよびその使用
DK04727873T DK1616011T3 (da) 2003-04-18 2004-04-16 Kimære polypeptider og deres anvendelse
CY20071101640T CY1107115T1 (el) 2003-04-18 2007-12-28 Χιμαιρικα πολυπεπτιδια και χρηση αυτων
US12/616,859 US20110033384A1 (en) 2003-04-18 2009-11-12 Chimeric polypeptides and their use
JP2011051784A JP2011182792A (ja) 2003-04-18 2011-03-09 キメラポリペプチドおよびその使用
US14/479,045 US20150018409A1 (en) 2003-04-18 2014-09-05 Chimeric polypeptides and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.

Publications (1)

Publication Number Publication Date
ITMI20030821A1 true ITMI20030821A1 (it) 2004-10-19

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.

Country Status (16)

Country Link
US (3) US20060292629A1 (it)
EP (1) EP1616011B1 (it)
JP (2) JP4794432B2 (it)
KR (2) KR101360781B1 (it)
CN (1) CN100584950C (it)
AT (1) ATE374826T1 (it)
AU (1) AU2004230254B2 (it)
CA (1) CA2522525A1 (it)
CY (1) CY1107115T1 (it)
DE (1) DE602004009301T2 (it)
DK (1) DK1616011T3 (it)
ES (1) ES2293247T3 (it)
IT (1) ITMI20030821A1 (it)
PL (1) PL1616011T3 (it)
PT (1) PT1616011E (it)
WO (1) WO2004092194A2 (it)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
KR20070107034A (ko) * 2005-02-18 2007-11-06 아스트라제네카 아베 Ｃｈｋ1 억제제에 대한 반응성의 결정 방법
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
CN106255883B (zh) 2014-02-17 2019-10-08 克劳德贝尔纳里昂第一大学 表征患者对治疗性电离辐射的放射敏感性和组织反应的预测方法
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
MX2018012454A (es) * 2016-04-12 2019-06-10 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Constructos de fusion de mutasa de metilmalonil coenzima a (mcm) para el tratamiento de trastornos asociados con la deficiencia de mcm.
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
CN109562138B (zh) * 2016-05-27 2023-03-21 辛赛克斯公司 蛋白质界面
JP7185278B2 (ja) * 2016-06-09 2022-12-07 アルマ・マテール・ストゥディオルム・ウニベルシータ・ディ・ボローニャ 改変糖タンパク質ｂを有するヘルペスウイルス
KR20200018645A (ko) 2017-06-15 2020-02-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 비-바이러스 dna 삽입
IL274179B2 (en) 2017-10-27 2024-02-01 Univ California Targeted replacement of endogenous T cell receptors
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
KR20240099259A (ko) 2021-10-14 2024-06-28 아스널 바이오사이언시스, 인크. 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
WO2023111213A1 (en) 2021-12-16 2023-06-22 Rdp Pharma Ag Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
EP1147209A2 (en) * 1999-02-03 2001-10-24 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
JP2002539839A (ja) * 1999-03-31 2002-11-26 インヴィトロゲン・コーポレーション 転位ポリペプチドによる機能性タンパク質配列の送達
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
CA2497913C (en) * 2002-09-05 2014-06-03 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Also Published As

Publication number Publication date
ES2293247T3 (es) 2008-03-16
EP1616011A2 (en) 2006-01-18
WO2004092194A2 (en) 2004-10-28
KR101360781B1 (ko) 2014-04-24
US20150018409A1 (en) 2015-01-15
DE602004009301D1 (de) 2007-11-15
WO2004092194A3 (en) 2005-03-17
CY1107115T1 (el) 2012-01-25
ATE374826T1 (de) 2007-10-15
DK1616011T3 (da) 2008-02-04
CN100584950C (zh) 2010-01-27
JP4794432B2 (ja) 2011-10-19
AU2004230254A1 (en) 2004-10-28
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
DE602004009301T2 (de) 2008-07-17
CA2522525A1 (en) 2004-10-28
KR101247704B1 (ko) 2013-03-26
JP2006523448A (ja) 2006-10-19
KR20110074948A (ko) 2011-07-04
US20110033384A1 (en) 2011-02-10
EP1616011B1 (en) 2007-10-03
CN1768142A (zh) 2006-05-03
US20060292629A1 (en) 2006-12-28
KR20060003029A (ko) 2006-01-09
AU2004230254B2 (en) 2008-10-02
JP2011182792A (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
ITMI20030821A1 (it) Polipeptidi chimerici e loro uso.
WO2001083525A3 (en) Modified peptides, comprising an fc domain, as therapeutic agents
DE602004018782D1 (de) Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten
EA200100464A1 (ru) Модифицированные пептиды как терапевтические агенты
ATE408824T1 (de) Miniaturisierte zellenanordnung und verfahren und vorrichtung zum screening mittels zellen
WO2005108415A3 (en) Membrane associated molecules
Smith et al. Comparison of resin and solution screening methodologies in combinatorial chemistry and the identification of a 100 nM inhibitor of trypanothione reductase
AR052441A1 (es) Suspension no acuosa inyectable
PL2255834T3 (pl) Projektowanie rusztowania z zastosowaniem czynników zasiedlania
WO2005093080A3 (de) Nitrilhydratase aus rhodococcus
De Veer et al. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors
Miura et al. In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2, 4-amino acids targeting the SARS-CoV-2 main protease
WO2006069203A3 (en) Methods for proteomic profiling using non-natural amino acids
Siang Ong et al. Recent advances in synthesis and identification of cyclic peptides for bioapplications
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
López‐Vera et al. Novel α‐conotoxins from Conus spurius and the α‐conotoxin EI share high‐affinity potentiation and low‐affinity inhibition of nicotinic acetylcholine receptors
ATE306498T1 (de) Von zellen präsentierte peptide
Cetinel et al. Peptides to bridge biological-platinum materials interface
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
Hyun et al. RNA Grooves Can Accommodate Disulfide‐Bridged Bundles of α‐Helical Peptides
Battistuzzi et al. Redox reactivity of the heme Fe 3+/Fe 2+ couple in native myoglobins and mutants with peroxidase-like activity
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
WO2002044409A3 (en) Substrate linked directed evolution (slide)
WO2005042717A3 (en) Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods
WO2013162760A1 (en) Novel cyclotides with anticancer activity